- Conditions
- Ototoxicity, Drug-Induced
- Interventions
- ORC-13661, Placebo
- Drug
- Lead sponsor
- Kevin Winthrop
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 8
- States / cities
- San Francisco, California • Denver, Colorado • Baltimore, Maryland + 5 more
Clinical trials in San Francisco, California
This page shows live ClinicalTrials.gov search results for San Francisco, California, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Institutions in San Francisco
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Interventions
- Enfortumab Vedotin, Pembrolizumab, Intensity Modulated Radiation Therapy (IMRT), Transurethral Resection of Bladder Tumor, Cystoscopy (CS), Computed Tomography (CT), Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET)
- Drug · Biological · Radiation + 1 more
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Orellanine
- Drug
- Lead sponsor
- Oncorena AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 6
- States / cities
- Orange, California • Palo Alto, California • San Francisco, California + 3 more
- Conditions
- Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive
- Interventions
- Neladalkib (NVL-655), Alectinib
- Drug
- Lead sponsor
- Nuvalent Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 23
- States / cities
- Glendale, Arizona • Newport Beach, California • Orange, California + 19 more
- Conditions
- Obstructive Hypertrophic Cardiomyopathy (oHCM)
- Interventions
- Mavacamten
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Atezolizumab, Cisplatin, Vinorelbine, Docetaxel, Gemcitabine, Pemetrexed
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2026
- U.S. locations
- 45
- States / cities
- Fayetteville, Arkansas • Encinitas, California • Fountain Valley, California + 38 more
- Conditions
- Eosinophilic Oesophagitis
- Interventions
- Dupilumab, Placebo
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 15
- States / cities
- Murrieta, California • San Francisco, California • Jacksonville, Florida + 12 more
- Conditions
- Refractory Angina
- Interventions
- Arm 1: treatment with Shockwave Reducer, Arm 2 (control): Implantation procedure with no device implanted, Arm 3 (unblinded, non-randomized): Single arm registry
- Device · Other
- Lead sponsor
- Shockwave Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 72
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 57 more
- Conditions
- Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
- Interventions
- Biospecimen Collection, Bupropion Hydrochloride Controlled-release, Placebo Administration, Quality-of-Life Assessment, Questionnaire Administration
- Procedure · Drug · Other
- Lead sponsor
- University of Rochester NCORP Research Base
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 422 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 542
- States / cities
- Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 335 more
- Conditions
- Aortic Stenosis
- Interventions
- Decision Aid, Shared Decision Making Skills Training
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 65 Years to 85 Years
- Enrollment
- 1,300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 8
- States / cities
- San Francisco, California • Aurora, Colorado • Atlanta, Georgia + 5 more
- Conditions
- Mantle Cell Lymphoma; Non-Hodgkin Lymphoma
- Interventions
- zanubrutinib, bendamustine, rituximab
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 510 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2031
- U.S. locations
- 12
- States / cities
- Orange, California • Chicago, Illinois • Boston, Massachusetts + 9 more
- Conditions
- Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- Nivolumab, Sitravatinib, Docetaxel
- Biological · Drug
- Lead sponsor
- Mirati Therapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 577 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 133
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Glendale, Arizona + 109 more